{"filing":{"accession_number":"0001104659-26-097517","cik":"0000075252","ticker":"ACH","company_name":"ACCENDRA HEALTH INC/VA/","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"tm2622667d5_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/75252/000110465926097517/tm2622667d5_8k.htm"},"events":[{"id":28058,"run_id":25643,"accession_number":"0001104659-26-097517","anchor_item_number":"7.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"summary":"The disclosure centers on three capital allocation and governance updates: (1) decision not to implement an at-the-market equity issuance program, (2) opportunistic sale of two non-core assets (~$45M), and (3) CEO succession planning with expected announcement by mid-September 2026. While the asset sales are financial and the ATM decision relates to capital structure, the filing's primary focus is the CEO succession process—a governance matter—with the Board actively evaluating candidates to replace retiring CEO Pesicka. The succession announcement is material to investors assessing leadership continuity.","company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29854,"accession_number":"0001104659-26-097517","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The disclosure centers on three capital allocation and governance updates: (1) decision not to implement an at-the-market equity issuance program, (2) opportunistic sale of two non-core assets (~$45M), and (3) CEO succession planning with expected announcement by mid-September 2026. While the asset sales are financial and the ATM decision relates to capital structure, the filing's primary focus is the CEO succession process—a governance matter—with the Board actively evaluating candidates to replace retiring CEO Pesicka. The succession announcement is material to investors assessing leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:55:08.415379+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29854,"accession_number":"0001104659-26-097517","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The disclosure centers on three capital allocation and governance updates: (1) decision not to implement an at-the-market equity issuance program, (2) opportunistic sale of two non-core assets (~$45M), and (3) CEO succession planning with expected announcement by mid-September 2026. While the asset sales are financial and the ATM decision relates to capital structure, the filing's primary focus is the CEO succession process—a governance matter—with the Board actively evaluating candidates to replace retiring CEO Pesicka. The succession announcement is material to investors assessing leadership continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:55:08.415379+00:00","company_name":"ACCENDRA HEALTH INC/VA/","ticker":"ACH","filing_date":"2026-08-17"}]}